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Drug points
Vaccination reactions and thiomersal
Drs NEIL H Cox, W NEIL MORLEY (Department
of Dermatology, Royal Hospital for Sick Children,
Glasgow), and ANGELA FoRSYTHE (Contact Derma-
titis Investigation Unit, Belvidere Hospital, Glasgow)
write: We were interested to read the comments by
Dr Norman Begg (1 November, p 1155) on local
reactions to triple vaccine. We describe a patient who
illustrates a further possible cause for such reactions.
This girl had had a history of atopic dermatitis since
the age of 4 months and of asthma since the age of
2 years. Her sister had atopic dermatitis. The patient
developed an abscess at the site of her first triple
vaccine (DPT) injection, and two further DPT vac-
cinations in the foUowing 18 months caused severe
local reactions and exacerbation of dermatitis at
antecubital and popliteal fossae, wrists, and ankles. At
the age of 5 a booster vaccination to diphtheria alone
also caused a similar reaction. Patch testing was
performed when she was 5½2 because of possible
exacerbations of dermatitis related to footwear. The
only positive reaction was to thiomersal (1+ at 48 and
% hours), which is used as a preservative in vaccines.
Negative results were obtained to the European
standard battery, rubber, chemicals, footwear battery,
and other organomercurials (which may be used in
leather processing). This girl's adverse reactions to
DPTimmunisationswereprobablyduetothepertussis
component but this would not explain the recent
reaction to diphtheria vaccine alone. Local reactions
to diphtheria vaccine are rare in children under
2 years, as is allergic contact dermatitis, and a
clinically relevant positive patch test result must be
taken seriously. We therefore believe that the likely
cause of the recent vaccination reaction in this patient
was her allergy to thiomersal, even if the earlier
reactions toDPT vaccinationsweredue tothe pertussis
component.
Thiomersal 0-01% (thimerosal, merthiolate, sodium
ethylmercurithiosalicylate) is used as a preservative in
Trivax DPT vaccine (Wellcome) and is present in all
brands of diphtheria, pertussis, and tetanus vaccines
available in the UK. In the past five years 56 patients
referred to the contact dermatitis investigation unit
have had positive patch test reactions to thiomersal
(about 1% of patients). As in most series, many of
these are not clinically relevant (in adults local
reactions to contact lens soaking solutions, eyedrops,
or nasal drops are the usual presentation of allergic
contact dermatitis due to thiomersal). It is possible
that many positive patch test reactions to thiomersal
may be due to sensitisation at the time ofvaccinations.
Make a comparison possible: ceruletide
Dr PAUL BINGHAM (Nazareth Hospital, Nazareth,
Israel) writes: I was pleased that Drs Raffaele Trita-
pepe and Carlodi Padova (25 October, p 1102) shared
their experience with irrigation plus ceruletide in the
treatment of retained biliary stones, but what a pity
they did not make their data comparable with that in
the paper they were commenting on. In that paper the
number of patients cured by one treatment was stated
(6 September, p 595). Drs Tritapepe and Padova give
only details of stones dissolved, and it is mathematic-
ally possible that they also had only an initial 30% cure
rate. Surely it is vital that when original data are given
in comment on a paper it is presented in a wav that it
can be compared with that paper, especially if the
details are readily available. This is another issue
touching the quality of research.'
I Dickersin K, Hewitt P. Look before you quote. Br Med J
1986;293:1000-2.
Desensitising vaccines
Dr J H TOOGOOD (Allergy Clinic, Victoria Hospital,
London, Ontario N6A 4G5) writes: The CSM Update
on densensitising vaccines points out the risk of
fatal anaphylaxis as a complication of desensitisaiion
therapy (11 October, p 948). The data presented
suggest that the incidence of these deaths in the
United Kingdom might have been increasing in recent
years. Factors other than the antigen per se may
contribute to this problem. For example, ,B adrenergic
blockade increases the severity of and mortality from
experimental anaphylaxis'l3 and in clinical practice
exceptionally severe or fatal anaphylactic reactions
have been triggered by desensitisation injections given
to patients receiving , blocker therapy for an un-
related condition."7
Pharmacological , blockade interferes with the
normal "shut off"' mechanisms that modulate the
synthesis and release ofanaphylaxis mediators,2 8 9 and
a relatively trivial antigenic challenge may trigger
a massive and persisting discharge of mediators.
Furthermore, the , blockade abrogates the effective-
ness of the adrenergic drugs on which one normally
relies to rapidly control the anaphylaxis.2 This associa-
tion between , blocker treatment and augmented
anaphylactic sensitivity is being increasingly recog-
nised in American and Canadian reports. It would be
worth re-examining the data in the CSM Update
to determine whether any of the 26 patients who
died from anaphylaxis were receiving concomitant ,B
blocker therapy. The temporal association between
the increase in the number of fatal reactions to
desensitisation reported in the United Kingdom and
the increasingly widespread use of 0 blocker drugs
might be more than coincidental.
1 Nisam MR, Zbinden Z, Chesrown S, Barnett D, and Gold WM.
Distribution and pharmacological release of histamine in
canine lung in vivo. J7 Appl Physiol 1978;44:455-63.
2 Toogood JH. Beta-blocker therapy and the risk of anaphylaxis.
Can Med Assoc_J (in press).
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47:35-7.
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system in allergic disease. In: Kaplan AP, ed. Allergy. New
York: Churchill Livingstone, 1985:199-213.
9 Assem ASK. Adrenergic mechanisms and immediate-type
allergy. Clin Allergy 1974;4:185-94.
Prescribing in pregnancy
Dr T PULLAR (Department of Medicine, General
Infirmary, Leeds LS1 3EX) writes: Dr Peter Rubins
(29 November, p 1415) classified non-steroidal anti-
inflammatory drugs in his category of drugs which
are present in breast milk but reach the baby in
insignificant dose. There has been one report of
convulsions in a baby whose mother was taking
indomethacin while breast feeding and it was argued
that this reaction may have been related to reduced
glucuronidation in neonates resulting in accumula-
tion.' Needs and Brooks therefore recommend
avoidance of indoleacetic acids during lactation, and
in view of the plethora of alternative agents this is
reasonable advice.2
I Eeg-Olofsson 0, Malmros 1, Elwin C-E, Steen B. Convulsions in
a breast-fed infant after maternal indomethacin. Lancet 1978;
ii:215.
2 Needs CJ, Brooks PM. Antirheumatic medication during lacta-
tion. BrJ3 Rheumatol 1985;24:291-8.
Antitetanus vaccination
Drs S C ROBERTS andWM SHEPHERD (Department of
Clinical Immunology and Chemotherapy, Wellcome
Research Laboratories, Beckenham, Kent BR3 3BS)
write: We would like to comment on two recent Any
Question replies about antitetanus vaccination (18
October, p 1020; 1 November, p 1155). Tetanus
toxoid is a very effective immunogen but the duration
of protection depends on the antigen content and
formulation, on the number and scheduling of doses,
and on individual variation both in the initial immune
response and in the persistence of circulating tetanus
antibodies. Computation of antitoxin regression rates
indicates that in eight years antitoxin titres below the
accepted minimum protective level (001U/ml) would
be predicted in 0-1% of a population receiving five
doses of standard vaccine in a routine course.' As
tetanus is a non-transmissible disease for which there
is no herd immunity, the desired goal should be
protective antitoxin concentrations in all individuals.
Thus it is generally recommended that subjects be
boosted at intervals of no longer than 10 years.
The second point with which we would take issue
concerns the use of skin tests. Dr Norman Begg
(p 1155) suggests that these might be used to investi
gate hyperimmunisation against tetanus; however,
positive cutaneous reactions can occur in under-
immunised subjects as well as in those who have
shown no clinical reactivity to prior tetanus immunisa-
tions.2 Skin tests in the individual case are therefore of
little value in determining immunisation state or in
predicting future reactivity to tetanus vaccination.
Apparent reactors to tetanus vaccination should be
given 0-1 ml doses of fluid tetanus toxoid (or tetanus/
diphtheria toxoid for infants). This reduced dose
administered intradermally is less reactive and is
sufficient to promote a booster response.3 (Fluid
toxoid is ineffective, however, when administered
with tetanus immunoglobulin, and adsorbed vaccine
should accompany passive prophylaxis. Adsorbed
vaccines should never be administered intradermally.)
I Peebles TC, Levine L, Eldred MC, Edsall G. Tetanus-toxoid
emergency boosters-a reappraisal. N EnglJ Med 1969;280:
57581.
2 White WG, Barnes GM, Barker E, et al. Reactions to tetanus
toxoid. J Hyg (Camb) 1973;71:283-97.
3 Ruegsegger JM. Further observations on the prevalence of
tetanus antitoxin. Arch Intem Med 1960;106:410-6.
Bilateral scopolamine mydriasis in a
traveller
Drs GABRIELLA MARIA MARCON and FERDINANDO
SCHIAVO (Ospedale Civile di Udine, 15-Udine, Italy)
write: Scopolamine, an anticholinergic agent with an
antiemetic action used to combat motion sickness, has
been available since 1981 in the form of slow release
adhesive for application behind the ears. Applied on
one side two hours before travelling the strips ensure
transdermal absorption ofthe drug for up to 72 hours,'
which should avert its side effects, provided that the
instructions are complied with strictly. It is important
not to touch the adhesive surface ofthe strips, to apply
the latter with dry hands, and to wash the hands well
after applying or removing them. Moreover, if protec-
tion is needed for more than 72 hours a second strip
may be applied in a different area behind the ears.
A 46 year old woman with a history of migraine and
mild hypertension was admitted in August 1985
because of bilateral amblyopia, nausea, vomiting,
subjective vertigo, dryness of the mouth, and intense
dragging headache refractory to drugs. The symptom
complex had appeared four days before, during a
coach trip to France, and had later worsened. On
admission the patient presented bilateral mydriasis
unreactive to light, accommodation, or convergence
and mild drowsiness, which, combined with the
intense headache, made proper history taking impos-
sible. Only in conversation with the husband some
hours later did it emerge that the patient had used the
scopolamine strips to prevent motion sickness, two
every 72 hours, had repeatedly "rubbed" them to
heighten the effect, and had not kept to the instruc-
tions. The clinical signs and symptoms cleared 36
hours after admission on rehydration therapy alone.
Only one case of mydriasis due to transdermal
scopolamine has been reported to date and that was
unilateral, in a 9 year old girl who had applied the
strips on one side only, that of the subsequent
mydriasis.2 We attribute the side effects in our case to
the transdermal mode of application rather than to
direct penetration of the nervous structures by the
drug.
I Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G.
Transdermal scopolamine in the prevention of motion sickness
at sea. Clin Phannacol Ther 1981 ;29:414-9.
2 Lebuiisson DA, Risvegliato M. La mydriase unilaterale du
voyageur. L.a Presse Medicake 1983;1-2:2214.
